130 related articles for article (PubMed ID: 3428307)
1. Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.
Malcolm SL; Allen JG; Bird H; Quinn NP; Marion MH; Marsden CD; O'Leary CG
Eur Neurol; 1987; 27 Suppl 1():28-35. PubMed ID: 3428307
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.
Crevoisier C; Hoevels B; Zürcher G; Da Prada M
Eur Neurol; 1987; 27 Suppl 1():36-46. PubMed ID: 3428308
[TBL] [Abstract][Full Text] [Related]
3. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier C; Monreal A; Metzger B; Nilsen T
Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
5. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
[TBL] [Abstract][Full Text] [Related]
6. The hydrodynamically balanced system: a novel principle of controlled drug release.
Erni W; Held K
Eur Neurol; 1987; 27 Suppl 1():21-7. PubMed ID: 3322836
[TBL] [Abstract][Full Text] [Related]
7. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
Chouza C; Romero S; de Medina O; Aljanati R; Scarmelli A; Caamano JL; Gonzales Panizza V
Eur Neurol; 1987; 27 Suppl 1():59-67. PubMed ID: 3428309
[TBL] [Abstract][Full Text] [Related]
8. Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
Rinne UK
Eur Neurol; 1987; 27 Suppl 1():120-5. PubMed ID: 3428305
[TBL] [Abstract][Full Text] [Related]
9. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
Eur Neurol; 1987; 27 Suppl 1():68-72. PubMed ID: 3428310
[TBL] [Abstract][Full Text] [Related]
10. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
Poewe WH; Lees AJ; Stern GM
Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
[TBL] [Abstract][Full Text] [Related]
12. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
Jansen EN; Meerwaldt JD; Heersema T; van Manen J; Speelman JD
Eur Neurol; 1987; 27 Suppl 1():88-92. PubMed ID: 3322841
[TBL] [Abstract][Full Text] [Related]
13. Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
Fischer PA; Baas H
Eur Neurol; 1987; 27 Suppl 1():81-7. PubMed ID: 3322840
[TBL] [Abstract][Full Text] [Related]
14. Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
Nordera GP; Lorizio A; Lion P; Durisotti C; D'Andrea G; Ferro-Milone F
Eur Neurol; 1987; 27 Suppl 1():76-80. PubMed ID: 3322839
[TBL] [Abstract][Full Text] [Related]
15. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
[TBL] [Abstract][Full Text] [Related]
16. A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.
Graham JS; Henderson JM; Morris JG; Yiannikas C
Aust N Z J Med; 1991 Feb; 21(1):11-5. PubMed ID: 2036070
[TBL] [Abstract][Full Text] [Related]
17. Effects of food on the pharmacokinetics of levodopa in a dual-release formulation.
Crevoisier C; Zerr P; Calvi-Gries F; Nilsen T
Eur J Pharm Biopharm; 2003 Jan; 55(1):71-6. PubMed ID: 12551706
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
[TBL] [Abstract][Full Text] [Related]
19. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
Quinn NP; Marion MH; Marsden CD
Eur Neurol; 1987; 27 Suppl 1():105-13. PubMed ID: 3322834
[TBL] [Abstract][Full Text] [Related]
20. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
Lees AJ
Eur Neurol; 1987; 27 Suppl 1():126-34. PubMed ID: 3428306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
